RxDoctor Payments Data

Susan Berner, MD

Geriatric Medicine · Oakwood, OHNPI 1952384505

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $331 of the $419 with a category attached, or 79.1%. 3 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 37.6% of the total.

$419in general payments, 2019–2025

Across 18 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$158
  • AbbVie$136
  • Johnson & Johnson$125

What the payments were for

  • Food & beverage$33179%
  • Education$8721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.5$158
AbbVie2$136
Johnson & Johnson11$125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$419 in reported general payments places this provider in the 65th percentile of 146 geriatric medicine providers in Ohio.

See all geriatric medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$405,705
Medicare patients
985
Services billed
3,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban3,007$1,088,515
IngrezzaValbenazine Tosylate164$696,349
Invega SustennaPaliperidone Palmitate190$640,210
XifaxanRifaximin112$191,072
XareltoRivaroxaban436$160,896
NuedextaDextromethorphan Hbr/Quinidine183$149,967
TrulicityDulaglutide165$134,892
NuplazidPimavanserin Tartrate40$132,761
MyrbetriqMirabegron466$126,012
JardianceEmpagliflozin306$112,129
Trelegy ElliptaFluticasone/Umeclidin/Vilanter158$105,775
Divalproex Sodium2,819$104,496
Humira(Cf) PenAdalimumab14$102,402
JanuviaSitagliptin Phosphate289$99,032
Avonex Pen (4 Pack)Interferon Beta-1a11$96,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$125$801,106626 claims
AbbVieCreon, Vraylar$136$62,239118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 146 geriatric medicine providers in Ohio.

Other geriatric medicine in Oakwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →